🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise around the world, with estimates suggesting more than 82 million instances annually. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the face of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists hope that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in the same week. This medication, which is employed against UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

As per findings detailed in a prominent scientific publication, the new drug eradicated the vast majority of uncomplicated infections. This puts it on an equal footing with the current standard treatment, which combines two antibiotics. The research included nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in a wide range of developing nations.

Medical professionals treating patients have voiced hope. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is considered vital to alleviate the strain of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.